Comparison of antibody responses following natural infection with Severe Acute Respiratory Syndrome Coronavirus 2 or receipt of CoronaVac or ChAdOx1 (AZD1222) vaccination in Chiang Mai, Thailand

Sayamon Hongjaisee; Kriangkrai Chawansuntati; Patumrat Sripan; Kritsadee Rattanathammethee; Supachai Sakkhachornphop; Romanee Chaiwarith; Tavitiya Sudjaritruk; Khuanchai Supparatpinyo; Jiraprapa Wipasa

doi:10.1016/j.jvacx.2023.100305

Comparison of antibody responses following natural infection with Severe Acute Respiratory Syndrome Coronavirus 2 or receipt of CoronaVac or ChAdOx1 (AZD1222) vaccination in Chiang Mai, Thailand

Vaccine X. 2023 Aug:14:100305. doi: 10.1016/j.jvacx.2023.100305. Epub 2023 Apr 20.

Authors

Sayamon Hongjaisee¹, Kriangkrai Chawansuntati¹, Patumrat Sripan¹, Kritsadee Rattanathammethee¹, Supachai Sakkhachornphop¹, Romanee Chaiwarith², Tavitiya Sudjaritruk³, Khuanchai Supparatpinyo¹, Jiraprapa Wipasa¹

Affiliations

¹ Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
² Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
³ Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Abstract

Background: In Thailand, early vaccination initiatives for SARS-CoV-2 relied on CoronaVac (Sinovac Life Sciences) and ChAdOx1 (Oxford-AstraZeneca) vaccines. However, the data of immunogenicity of these two vaccines in Thai populations is limited. This real time, head-to-head comparative study was conducted to investigate antibody (Ab) responses to SARS-CoV-2 following infection or receipt of either CoronaVac or ChAdOx1 vaccination in Chiang Mai, Thailand.

Methods: Sera was collected within two months from participants having a history of documented SARS-CoV-2 infection or at one month after the second dose of CoronaVac vaccine. Sera from participants with a history of receiving one dose of ChAdOx1 vaccination was collected twice, at one month following each vaccine dose. Neutralizing antibodies (NAbs) were assessed using the surrogate neutralization test and anti-spike protein antibodies were assessed using an in-house enzyme-linked immunosorbent assay.

Results: The prevalence of NAbs against SARS-CoV-2 was 92.1 %, 95.7 %, 64.1 % and 100 % in the infection group, CoronaVac group, ChAdOx1 group after 1st dose, and ChAdOx1 group after 2nd dose, respectively. The inhibition rate in individuals receiving two doses of ChAdOx1 vaccine (90.8%) was significantly higher than individuals who had recovered from natural infection (71.7%) or individuals who had received two doses of CoronaVac vaccine (66.7%). The prevalence of anti-spike Abs was 97.4 %, 97.8 %, 97.4 % and 100 % in the infection group, CoronaVac group, ChAdOx1 group after 1st dose, and ChAdOx1 group after 2nd dose, respectively. Significantly higher levels of anti-spike Abs were observed in the ChAdOx1 group after two doses of vaccination (1975 AU/mL) compared to those who had recovered from natural infection (468.5 AU/mL) and individuals who had received CoronaVac (554.4 AU/mL). Neutralizing activity had a statistically significant positive correlation with levels of anti-spike Abs.

Conclusions: ChAdOx1 vaccine may provide superior immunogenicity than CoronaVac and natural infection.

Keywords: ChAdOx1; CoronaVac; Coronavirus disease (COVID-19); Neutralizing antibodies; Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).